Clinical Trials Browser

Recruiting × Head and Neck Neoplasms × Docetaxel × Clear all

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07209189 2026-03-09

(NeoScorch HN)

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07358806 2026-01-22

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

51 enrolled

BreastGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms

NCT05076760 2025-08-29

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Phase 1 Recruiting

40 enrolled

BreastDermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT06940180 2025-06-26

Toripalimab With Chemotherapy for Sinus Cancer

Phase 2 Recruiting

20 enrolled

Head & Neck

Sinonasal undifferentiated carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Paranasal Sinus Neoplasms

NCT05726370 2025-06-22

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Phase 2 Recruiting

28 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03326947 2024-02-20

Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

Phase 2 Recruiting

60 enrolled

Head & Neck

Head and Neck Neoplasms

Clinical Trials

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

(NeoScorch HN)

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Toripalimab With Chemotherapy for Sinus Cancer

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC